Oncodesign® Presents its Latest Scientific Advances at the AACR Annual Conference
News Apr 19, 2010
Oncodesign, a specialist in the identification of novel cancer therapies, announces that it will present eight scientific posters at the annual conference of the American Association for Cancer Research in Washington DC, April 17-20.
As in previous years, Oncodesign is showcasing its latest technological advances at the AACR. The company’s translational research platform is focused on two main technology areas: the development of new experimental models and new pharmaco-imaging tools. In the field of preclinical models, Oncodesign is presenting its new platform for the production of “chi-Mice”, humanized chimeric animals.
“These models combine our research into grafting tumors directly from patients and the reconstitution of a human hematological and immune system in a severely immunodeficient mouse,” said Philippe Genne, CEO of Oncodesign. “Our mouse humanization platform means our customers can have these models in house or let us carry out their preclinical evaluation in our labs.” The procedures and characterization of the humanized models are presented in the two posters produced in conjunction with Oncodesign’s scientific partners (#394, #4169).
Oncodesign’s core business is the evaluation of new therapies in oncology. This is represented by four posters produced in conjunction with the company’s customers (#571, #1367, #5459, #5490). Oncodesign’s world-class in vitro and in vivo pharmacology platform has made significant contributions to the biodistribution and the efficacy of Oncodesign’s customers’ products. In the context of this translational research, Oncodesign’s scientific team will present its results with biomarkers of antitumoral efficacy using MRI and with serum biomarkers for the development of bone metastases in tumors of the prostate in the Nude rat.
The last innovation presented is the process of translational drug discovery which combines the Nanocyclix® medicinal chemistry technology and the in vivo pharmacological approach (#740). “Our goal is to offer our customers access to highly specific kinases and to discover new therapeutic molecules or imaging biomarkers using biological assays very close to clinical reality.”
Novel Chemistry Technique Simplifies Late-Stage Modification of Drug CompoundsNews
Chemists at The Scripps Research Institute (TSRI) have invented a technique that overcomes a long-standing problem in organic chemistry and should streamline the process of discovery and development for many new drugs.READ MORE
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE